A new study published in Global Spine Journal, carried out by researchers from Johns Hopkins together with collaborators from the All India Institute of Medical Sciences (AIIMS) in New Delhi, has put an unusual detail on the radar of spine surgeons: the long-term use of inhaled corticosteroids in asthma patients.
At first sight, this may sound like a minor point. Inhaled steroids are common, widely used and generally considered much safer than systemic steroids. But the study found something worth noting. Among patients undergoing lumbar fusion, those with asthma who were on maintenance inhaled corticosteroids had a higher rate of revision surgery at two and five years.
Interestingly, asthma itself did not appear to be the key issue. Asthmatic patients who were not using inhaled corticosteroids showed revision rates closer to patients without asthma. That distinction is important, because it shifts the discussion away from asthma as a disease and toward the possible effect of chronic medication exposure, bone quality and fusion biology.
The finding should be treated with caution. This was not a trial proving that inhaled corticosteroids cause failed fusion. It was an observational signal. It also does not mean that patients should stop their asthma medication before spine surgery. That would be the wrong conclusion. But for the spine market, the study is still relevant.
Lumbar fusion is often discussed in terms of implants: cages, screws, rods, expandable devices, fixation systems and new surgical technologies. All of that matters. But none of it works in isolation. A fusion construct is placed into a patient, and that patient brings his or her own biology: bone density, healing capacity, comorbidities, medication history and risk profile.
That is where this study becomes interesting. It reinforces a trend that is already becoming more visible in spine surgery: the outcome of a fusion procedure may depend as much on patient preparation as on the device itself.
For surgeons and hospitals, this may support a more systematic review of bone health and medication history before lumbar fusion. For industry, it is another sign that the conversation around fusion is moving beyond the implant alone. Technologies that help reduce revision risk, improve fixation in compromised bone, support biologic healing or identify high-risk patients before surgery may become increasingly important.
Revision surgery remains one of the most expensive and difficult problems in spine care. If a common therapy such as long-term inhaled corticosteroid use may help identify a higher-risk patient group, it deserves attention.
In spine surgery, the implant remains essential. But the patient’s biology may be just as important.
###
Legal Disclaimer:
Content published on SPINEMarketGroup (thespinemarketgroup.com) is provided for informational purposes only and on an “as is” basis, without warranties of any kind. We do not guarantee the accuracy, completeness, legality, or reliability of any information, images, videos, links, or third-party materials featured on the site. Any views or claims expressed in contributed content or press releases belong to their respective authors or sources. For copyright concerns, factual corrections, or content-related complaints, please contact us directly for review.